English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18054/20253 (89%)
Visitors : 24216433      Online Users : 55
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34654


    標題: Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials
    作者: Lee, Mei-Chuan
    Hua, Yi-Ming
    Yang, Chun-Ting
    Kuo, Fang-Hsiu
    Chang, Wei-Ting
    Tang, Hsin-Ju
    Toh, Han Siong
    Lin, Yu-Min
    Chen, Sih-Yao
    Chang, Hung-Yu
    Liao, Chia-Te
    貢獻者: Chi Mei Hospital
    National Cheng Kung University
    National Cheng Kung University
    Chi Mei Hospital
    National Cheng Kung University
    Southern Taiwan University of Science & Technology
    Chang Gung University of Science & Technology
    Chi Mei Hospital
    Department of Health and Nutrition, Chia Nan University of Pharmacy & Science
    National Yang Ming Chiao Tung University
    Cheng Hsin General Hospital
    關鍵字: cotransporter 2 inhibitors
    empagliflozin
    risk
    日期: 2022
    上傳時間: 2023-12-11 14:03:09 (UTC+8)
    出版者: LIPPINCOTT WILLIAMS & WILKINS
    摘要: Background:Some sodium-glucose co-transporter-2 (SGLT2) inhibitors showed benefits on heart failure (HF), but different SGLT2/SGLT1 selectivity might influence the treatment effect. This study aimed to meta-analyze the treatment effects of SGLT2 inhibitors and the diversity of receptor selectivity for patients with and without HF. Methods:Randomized controlled trials were searched in PubMed, Embase, Cochrane databases and ClinicalTrials.gov registry from inception to October 2020. The interest outcomes were analyzed with random-effects models and presented with a risk ratio (RR) and 95% confidence interval (CI). Subgroup analyses examined the treatment effects among SGLT2 inhibitors with different SGLT2/SGLT1 selectivity. Results:The final analyses included 10 trials and 52,607 patients. The RR of total cardiovascular (CV) death or hospitalization for HF (HHF) between SGLT2 inhibitors and placebo was 0.79 (95% CI 0.74-0.84, I-2 = 31%). With SGLT2 inhibitors, HF patients had reduced mortality risks (RR 0.89, 95% CI 0.80-0.99, I-2 = 0), and non-HF patients had lower risks of major adverse CV events (RR 0.92, 95% CI 0.85-0.99, I-2 = 0). The risk reduction of HHF was consistent in groups of HF (RR 0.72, 95% CI 0.64-0.80, I-2 = 8%) and non-HF (RR 0.74, 95% CI 0.61-0.89, I-2 = 0), but the effect of the low SGLT2/SGLT1 selectivity inhibitor was insignificant in non-HF patients. Conclusion:The efficacy of SGLT2 inhibitors on risk reduction of total CV death or HHF is consistent with the previous studies. The regimen is beneficial for reducing mortality in patients with HF and major adverse CV events in those without HF. Different SGLT2/SGLT1 selectivity may differ in the treatment effects in patients with and without HF.
    關聯: MEDICINE, v.101, n.51, e32489
    Appears in Collections:[保健營養系(所) ] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML102View/Open
    MD.0000000000032489.pdf1555KbAdobe PDF51View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback